New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 7, 2012
07:24 EDTBRLIBio-Reference Labs downgraded to Underperform from Neutral at Macquarie
Macquarie downgraded Bio-Reference Labs following the Q4 miss citing margin pressure and reimbursement cuts. Price target is $25.
News For BRLI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 21, 2015
14:16 EDTBRLIOPKO Health shares look pricey, Barron's says
Investors should steer clear of OPKO Health (OPK) and Bio-Reference Labs (BRLI) in light of their recent merger agreement, Barron's contends in a feature article. Though OPKO hopes to push its prostate cancer test, similar products have performed poorly on the market, and Barron's advises "only those who believe that [CEO and chairman Phillip Frost] can work miracles" to own the stock. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use